Definitions
Sorry, no definitions found. Check out and contribute to the discussion of this word!
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word embonate.
Examples
-
The marketing authorisation (MA) to this 6-month sustained-release formulation of Decapeptyl (R) (triptorelin embonate [1] 22.5 mg) was granted on
THE MEDICAL NEWS 2010
-
Debiopharm developed and registered the 1 - and 3-month sustained release formulations of triptorelin embonate in Europe and the U.S.
-
The marketing authorisation (MA) to this 6-month sustained-release formulation of Decapeptyl (R) (triptorelin embonate [1] 22.5 mg) was granted on 10 November 2009 by the French regulatory authorities (Agence Francaise de Securite Sanitaire des Produits de Sante, AFSSAPS) for the treatment of locally advanced and metastatic hormone-dependent prostate cancer.
-
Debiopharm developed and registered the 1 - and 3-month sustained release formulations of triptorelin embonate in Europe and the U.S.
-
The marketing authorisation (MA) to this 6-month sustained-release formulation of Decapeptyl (R) (triptorelin embonate [1] 22.5 mg) was granted on 10
-
Debiopharm developed and registered the 1 - and 3-month sustained release formulations of triptorelin embonate in Europe and the U.S. The active substance in Decapeptyl
-
Debiopharm developed and registered the 1 - and 3-month sustained release formulations of triptorelin embonate in Europe and the U.S.
-
The marketing authorisation (MA) to this 6-month sustained-release formulation of Decapeptyl (R) (triptorelin embonate [1] 22.5 mg) was granted on 10
-
Triptorelin embonate 22.5 mg is a new 6-month-formulation of a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer, developed by Debiopharm Group.
-
Triptorelin embonate 22.5 mg is a new 6-month-formulation of a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer, developed by Debiopharm Group.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.